Cargando…
Ion channels and pain in Fabry disease
Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299890/ https://www.ncbi.nlm.nih.gov/pubmed/34284652 http://dx.doi.org/10.1177/17448069211033172 |
_version_ | 1783726353406754816 |
---|---|
author | Weissmann, Carina Albanese, Adriana A Contreras, Natalia E Gobetto, María N Castellanos, Libia C Salinas Uchitel, Osvaldo D |
author_facet | Weissmann, Carina Albanese, Adriana A Contreras, Natalia E Gobetto, María N Castellanos, Libia C Salinas Uchitel, Osvaldo D |
author_sort | Weissmann, Carina |
collection | PubMed |
description | Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry disease is neuropathic pain. Accumulation of Gb3 has been documented in dorsal root ganglia (DRG) as well as other neurons, and has lately been associated with the mechanism of pain though the pathophysiology is still unclear. Small fiber (SF) neuropathy in FD differs from other entities in several aspects related to the perception of pain, alteration of fibers as well as drug therapies used in the practice with patients, with therapies far from satisfying. In order to develop better treatments, more information on the underlying mechanisms of pain is needed. Research in neuropathy has gained momentum from the development of preclinical models where different aspects of pain can be modelled and further analyzed. This review aims at describing the different in vitro and FD animal models that have been used so far, as well as some of the insights gained from their use. We focus especially in recent findings associated with ion channel alterations -that apart from the vascular alterations-, could provide targets for improved therapies in pain. |
format | Online Article Text |
id | pubmed-8299890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82998902021-08-06 Ion channels and pain in Fabry disease Weissmann, Carina Albanese, Adriana A Contreras, Natalia E Gobetto, María N Castellanos, Libia C Salinas Uchitel, Osvaldo D Mol Pain Review Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry disease is neuropathic pain. Accumulation of Gb3 has been documented in dorsal root ganglia (DRG) as well as other neurons, and has lately been associated with the mechanism of pain though the pathophysiology is still unclear. Small fiber (SF) neuropathy in FD differs from other entities in several aspects related to the perception of pain, alteration of fibers as well as drug therapies used in the practice with patients, with therapies far from satisfying. In order to develop better treatments, more information on the underlying mechanisms of pain is needed. Research in neuropathy has gained momentum from the development of preclinical models where different aspects of pain can be modelled and further analyzed. This review aims at describing the different in vitro and FD animal models that have been used so far, as well as some of the insights gained from their use. We focus especially in recent findings associated with ion channel alterations -that apart from the vascular alterations-, could provide targets for improved therapies in pain. SAGE Publications 2021-07-20 /pmc/articles/PMC8299890/ /pubmed/34284652 http://dx.doi.org/10.1177/17448069211033172 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Weissmann, Carina Albanese, Adriana A Contreras, Natalia E Gobetto, María N Castellanos, Libia C Salinas Uchitel, Osvaldo D Ion channels and pain in Fabry disease |
title | Ion channels and pain in Fabry disease |
title_full | Ion channels and pain in Fabry disease |
title_fullStr | Ion channels and pain in Fabry disease |
title_full_unstemmed | Ion channels and pain in Fabry disease |
title_short | Ion channels and pain in Fabry disease |
title_sort | ion channels and pain in fabry disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299890/ https://www.ncbi.nlm.nih.gov/pubmed/34284652 http://dx.doi.org/10.1177/17448069211033172 |
work_keys_str_mv | AT weissmanncarina ionchannelsandpaininfabrydisease AT albaneseadrianaa ionchannelsandpaininfabrydisease AT contrerasnataliae ionchannelsandpaininfabrydisease AT gobettomarian ionchannelsandpaininfabrydisease AT castellanoslibiacsalinas ionchannelsandpaininfabrydisease AT uchitelosvaldod ionchannelsandpaininfabrydisease |